Connecting clients, partners and patients to develop new treatments for diabetes and related metabolic diseases.

Science Driven Therapeutically Focused

Delivering on the Potential of Innovative Therapeutics for Metabolic Diseases

Advise • Advance • Achieve

Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network

ProSciento Services

Specialty consulting services for clinical development, regulatory strategy and licensing.
State-of-the-art clinical research facilities for metabolic drug and device clinical trials.
Full scope, comprehensive multi-site services to support metabolic clinical research programs.
Global network of partners connecting our clients to the most innovative research methods.

Subscribe to receive company updates.


June 7, 2017

ProSciento and OWL Metabolomics Form Strategic Collaboration Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment Read More »

May 30, 2017

ProSciento Appoints Dr. Kelvin Logan, Former Executive at INC Research and Quintiles, to its Board of Directors Read More »


View Our Presentation


November 7, 2017

Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development Read More »

September 14, 2017

NEJM article: Effects of 1x/weekly exenatide on CV outcomes in T2D Read More »

August 31, 2017

New CDC Data Shows US Adults Still Struggling with Obesity Read More »